JP2006508030A - ピリミジノン化合物、組成物および方法 - Google Patents

ピリミジノン化合物、組成物および方法 Download PDF

Info

Publication number
JP2006508030A
JP2006508030A JP2004502928A JP2004502928A JP2006508030A JP 2006508030 A JP2006508030 A JP 2006508030A JP 2004502928 A JP2004502928 A JP 2004502928A JP 2004502928 A JP2004502928 A JP 2004502928A JP 2006508030 A JP2006508030 A JP 2006508030A
Authority
JP
Japan
Prior art keywords
optionally substituted
methyl
alkyl
compound
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004502928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508030A5 (enExample
Inventor
ツォウ，ハン−ジエ
モーガンズ，デイヴィッド，ジェイ．，シー．，ジュニア
ナイト，スティーブン，デイヴィッド
ニューランダー，ケネス，エー．
ダーナク，ダッシーアント
アダムス，ニコラス，ディー．
バーグネス，ギュスターヴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of JP2006508030A publication Critical patent/JP2006508030A/ja
Publication of JP2006508030A5 publication Critical patent/JP2006508030A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2004502928A 2002-05-09 2003-05-02 ピリミジノン化合物、組成物および方法 Pending JP2006508030A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37965802P 2002-05-09 2002-05-09
PCT/US2003/013627 WO2003094839A2 (en) 2002-05-09 2003-05-02 Pyrimidinone compounds, compositions and methods

Publications (2)

Publication Number Publication Date
JP2006508030A true JP2006508030A (ja) 2006-03-09
JP2006508030A5 JP2006508030A5 (enExample) 2006-07-06

Family

ID=29420548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004502928A Pending JP2006508030A (ja) 2002-05-09 2003-05-02 ピリミジノン化合物、組成物および方法

Country Status (20)

Country Link
US (2) US7166595B2 (enExample)
EP (1) EP1503993A4 (enExample)
JP (1) JP2006508030A (enExample)
KR (1) KR20050036911A (enExample)
CN (1) CN100491358C (enExample)
AR (1) AR039985A1 (enExample)
AU (1) AU2003223786A1 (enExample)
BR (1) BR0309892A2 (enExample)
CA (1) CA2485148A1 (enExample)
IL (2) IL165046A0 (enExample)
IS (1) IS7520A (enExample)
MX (1) MXPA04011074A (enExample)
MY (1) MY140767A (enExample)
NO (1) NO20045043L (enExample)
NZ (1) NZ537076A (enExample)
PL (1) PL373412A1 (enExample)
RU (1) RU2004135554A (enExample)
TW (1) TW200406387A (enExample)
WO (1) WO2003094839A2 (enExample)
ZA (1) ZA200409881B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CA2468266A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
WO2003070701A2 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
KR20050036911A (ko) * 2002-05-09 2005-04-20 싸이토키네틱스, 인코포레이티드 화합물들, 방법 및 조성물
JP2005530806A (ja) * 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005538062A (ja) 2002-06-14 2005-12-15 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
DE602004021477D1 (de) * 2003-03-07 2009-07-23 Astrazeneca Ab Kondensierte heterocyclen und deren verwendungen
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
EP1682534A2 (en) * 2003-11-03 2006-07-26 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions, and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
AU2004305069C1 (en) 2003-12-19 2010-07-29 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2005222399A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
EP1732926B1 (en) 2004-04-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Mitotic kinesin inhibitors
DK1753723T3 (da) 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7375102B2 (en) * 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
UA84954C2 (ru) * 2004-07-22 2008-12-10 Astrazeneca Ab Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
MY141233A (en) 2004-08-18 2010-03-31 Astrazeneca Ab Enantiomers of selected fused heterocyclics and uses thereof
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
MX2007004699A (es) 2004-10-19 2007-06-14 Novartis Vaccines & Diagnostic Derivados de indol y bencimidazol.
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
TW200716102A (en) * 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
EP2091926B1 (en) 2006-11-13 2015-10-21 Novartis AG Substituted pyrazole and triazole compounds as ksp inhibitors
AU2008205169B2 (en) 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
EP2070932A1 (en) * 2007-12-13 2009-06-17 4Sc Ag Pyrazolotriazines
WO2011001115A1 (fr) * 2009-07-02 2011-01-06 Sanofi-Aventis Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
HUE036431T2 (hu) * 2010-03-04 2018-07-30 Merck Sharp & Dohme Katechin o-metil transzferáz gátlók és alkalmazásuk pszichotikus betegségek kezelésében
WO2011151701A1 (en) * 2010-05-31 2011-12-08 Council Of Scientific & Industrial Research 6 - methyl - 4 - phenyl - 5 - ( phenyl or cycloalkyl) carbamoyl - 1,2,3, 4 - tetrahydropyrimidin- 2 - one derivatives as antitubercular agents
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3083584B1 (en) 2013-12-19 2018-02-21 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in the treatment of tissue fibrosis
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
RU2021109549A (ru) 2014-08-29 2021-05-13 Тес Фарма С.Р.Л. ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2649141C2 (ru) * 2015-04-20 2018-03-30 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017066402A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
SG11201804674UA (en) 2015-12-16 2018-06-28 Bristol Myers Squibb Co Heteroarylhydroxypyrimidinones as agonists of the apj receptor
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US12378203B2 (en) 2018-11-01 2025-08-05 Ahammune Biosciences Private Limited Imidazole compounds, process for the synthesis and uses thereof
CN112843058A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用
CN113897631B (zh) * 2021-10-24 2023-05-09 昆明学院 电化学合成吡啶-2-酮衍生物的方法
CN118530185B (zh) * 2024-07-25 2024-10-22 山东仁一生物科技有限责任公司 一种制备4-羟基-6-甲基嘧啶的方法

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5466689A (en) * 1977-10-21 1979-05-29 Bayer Ag Novel substituted pyrimidinyl*thiono**thiol* phosphoric acid esters and esterramidos* their manufacture and use thereof as insecticide and tickicide
JPS5821669A (ja) * 1981-07-30 1983-02-08 Tetsuzo Kato ２−（１−アシルアミノアルキル）−６−メチル−４（３ｈ）−ピリミジノンの製法
JPS6019789A (ja) * 1983-07-12 1985-01-31 Kyorin Pharmaceut Co Ltd イミダゾ〔１，５−ａ〕ピリミジン誘導体
JPS6143191A (ja) * 1984-08-07 1986-03-01 Kyorin Pharmaceut Co Ltd イミダゾ〔１，５−ａ〕ピリミジン誘導体
JPS62135473A (ja) * 1985-12-06 1987-06-18 Fujisawa Pharmaceut Co Ltd イミダゾ−ル縮合複素環化合物
JPH02218668A (ja) * 1988-12-15 1990-08-31 Imperial Chem Ind Plc <Ici> キナゾリン、その製法及び該化合物を含有する抗腫瘍作用を有する医薬組成物
JPH04147135A (ja) * 1990-10-10 1992-05-20 Konica Corp 新規な写真用カプラー
JPH04147134A (ja) * 1990-10-09 1992-05-20 Konica Corp 新規な写真用カプラー
JPH0649070A (ja) * 1991-07-23 1994-02-22 Kyorin Pharmaceut Co Ltd イミダゾ［１，５−ａ］ピリミジン誘導体
JPH09504010A (ja) * 1993-10-20 1997-04-22 ジ・アップジョン・カンパニー 抗関節炎剤および抗炎症剤としてのピリミジノン
WO2001016114A2 (en) * 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
WO2001019802A1 (fr) * 1999-09-16 2001-03-22 Tanabe Seiyaku Co., Ltd. Composes cycliques aromatiques azotes a six elements
WO2001019800A2 (en) * 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2001030768A1 (en) * 1999-10-27 2001-05-03 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001049287A1 (en) * 1999-12-30 2001-07-12 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001098278A1 (en) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002030462A2 (en) * 2000-10-13 2002-04-18 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
JP2002338466A (ja) * 2001-03-15 2002-11-27 Tanabe Seiyaku Co Ltd 医薬組成物
JP2004515544A (ja) * 2000-12-11 2004-05-27 藤沢薬品工業株式会社 キナゾリノン誘導体
JP2004536796A (ja) * 2000-12-11 2004-12-09 トゥラリック インコーポレイテッド Ｃｘｃｒ３アンタゴニスト
JP2005507876A (ja) * 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
JP2005510500A (ja) * 2001-10-26 2005-04-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ジヒドロキシピリミジンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
JP2005511543A (ja) * 2001-10-26 2005-04-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
JP2005525303A (ja) * 2001-12-06 2005-08-25 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (enExample) 1963-05-18
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
US3723432A (en) 1968-11-12 1973-03-27 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
US3962244A (en) 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4011324A (en) 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
DE3177130D1 (de) 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0333118Y2 (enExample) 1986-02-20 1991-07-12
DE3609598A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4729996A (en) 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
DE3721855A1 (de) 1987-03-12 1988-09-22 Merck Patent Gmbh Aminosaeurederivate
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US4808590A (en) 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
EP0341990B1 (en) 1988-05-10 1994-11-09 Imperial Chemical Industries Plc Cephalosporins, process for their preparation and pharmaceutical compositions
GB8820129D0 (en) 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
JPH05504969A (ja) 1990-02-13 1993-07-29 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル要素を含有するアンギオテンシン２アンタゴニスト類
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
AU640016B2 (en) 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
SG50693A1 (en) 1992-03-12 1998-07-20 Smithkline Beecham Plc Pharmaceuticals
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
WO1993023404A1 (en) 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
JPH06148835A (ja) 1992-11-04 1994-05-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその処理方法
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
AU6087894A (en) 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5401745A (en) 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5342944A (en) 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
US5589489A (en) 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
CA2113229C (en) 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
AU1831395A (en) 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
DE4413169C1 (de) * 1994-04-15 1995-05-11 Daimler Benz Ag Schaltvorrichtung für ein Zahnräderwechselgetriebe
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
JPH09165385A (ja) 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5891879A (en) 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
US5908930A (en) 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
WO1996039403A1 (en) 1995-06-05 1996-12-12 Neurogen Corporation 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles as dopamine receptor ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997008153A1 (en) 1995-08-30 1997-03-06 Otsuka Pharmaceutical Factory, Inc. Process for producing quinazolin-4-one derivatives
AU4858596A (en) 1995-09-15 1997-04-01 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
US6303615B1 (en) 1996-05-15 2001-10-16 Pfizer Inc 2,3 disubstituded-4(3H)-quinazolinones
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
AU5380398A (en) 1996-12-17 1998-07-15 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
ATE303997T1 (de) 1997-06-09 2005-09-15 Pfizer Prod Inc Chinazolin-4-on ampa antagonisten
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
DE69837264T2 (de) 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US5972929A (en) 1997-08-21 1999-10-26 Shiseido Co., Ltd. Quinazolinone derivative, hair growth promoter and external composition for skin using the same
US6207403B1 (en) 1998-01-08 2001-03-27 The Regents Of The University Of California Kinesin motor modulators derived from the marine sponge Adocia
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2335595A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
WO2000007017A2 (en) 1998-07-27 2000-02-10 President And Fellows Of Harvard College Method of high-throughput screening
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
US6197488B1 (en) 1999-07-21 2001-03-06 Eastman Kodak Company Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
EP1216233A1 (en) 1999-09-28 2002-06-26 MERCK PATENT GmbH Quinazolinones
EP1216235A1 (en) 1999-09-28 2002-06-26 MERCK PATENT GmbH Quinazolinones
EP1216243A1 (en) 1999-10-01 2002-06-26 Advanced Medicine, Inc. Quinazolinones and analogues and their use as local anesthetics
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2159488B1 (es) 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
US20020082268A1 (en) 2000-03-20 2002-06-27 Yun Gao Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU4966401A (en) 2000-03-30 2001-10-15 Curis Inc Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
AU2001275269B2 (en) 2000-06-09 2006-07-13 Osi Pharmaceuticals, Inc. Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1174430A1 (en) 2000-07-20 2002-01-23 Universität Konstanz Process for the preparation of heterocycles by using C1-building blocks
PL366335A1 (en) 2000-07-26 2005-01-24 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
EP1307201B1 (de) 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
CA2417635C (en) 2000-08-11 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2004529918A (ja) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
US7365199B2 (en) 2001-04-20 2008-04-29 Fujifilm Corporation Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US20030220338A1 (en) 2001-07-16 2003-11-27 Watkins Will J. Fungal efflux pump inhibitors
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
WO2003020280A2 (en) 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and use thereof in the treatment of cancer
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US7053216B2 (en) 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1465896A4 (en) 2001-12-06 2006-01-11 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
WO2003063800A2 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2003228283A1 (en) 2002-03-07 2003-09-22 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
JP4399269B2 (ja) 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
EP1513534A2 (en) 2002-04-04 2005-03-16 Cv Therapeutics, Inc. Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
KR20050036911A (ko) 2002-05-09 2005-04-20 싸이토키네틱스, 인코포레이티드 화합물들, 방법 및 조성물
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
IL165624A0 (en) 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
JP2005538062A (ja) 2002-06-14 2005-12-15 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
AU2003255529B2 (en) 2002-07-10 2008-11-20 Laboratoires Serono Sa Use of compounds for increasing spermatozoa motility
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2004022554A1 (en) 2002-09-07 2004-03-18 Celltech R & D Limited Quinazolinone derivatives
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
US20070149500A1 (en) 2003-01-17 2007-06-28 Han-Jie Zhou Compounds, compositions, and methods
DE602004021477D1 (de) 2003-03-07 2009-07-23 Astrazeneca Ab Kondensierte heterocyclen und deren verwendungen
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
EP1682534A2 (en) 2003-11-03 2006-07-26 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions, and methods
US20050152940A1 (en) 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5466689A (en) * 1977-10-21 1979-05-29 Bayer Ag Novel substituted pyrimidinyl*thiono**thiol* phosphoric acid esters and esterramidos* their manufacture and use thereof as insecticide and tickicide
JPS5821669A (ja) * 1981-07-30 1983-02-08 Tetsuzo Kato ２−（１−アシルアミノアルキル）−６−メチル−４（３ｈ）−ピリミジノンの製法
JPS6019789A (ja) * 1983-07-12 1985-01-31 Kyorin Pharmaceut Co Ltd イミダゾ〔１，５−ａ〕ピリミジン誘導体
JPS6143191A (ja) * 1984-08-07 1986-03-01 Kyorin Pharmaceut Co Ltd イミダゾ〔１，５−ａ〕ピリミジン誘導体
JPS62135473A (ja) * 1985-12-06 1987-06-18 Fujisawa Pharmaceut Co Ltd イミダゾ−ル縮合複素環化合物
JPH02218668A (ja) * 1988-12-15 1990-08-31 Imperial Chem Ind Plc <Ici> キナゾリン、その製法及び該化合物を含有する抗腫瘍作用を有する医薬組成物
JPH04147134A (ja) * 1990-10-09 1992-05-20 Konica Corp 新規な写真用カプラー
JPH04147135A (ja) * 1990-10-10 1992-05-20 Konica Corp 新規な写真用カプラー
JPH0649070A (ja) * 1991-07-23 1994-02-22 Kyorin Pharmaceut Co Ltd イミダゾ［１，５−ａ］ピリミジン誘導体
JPH09504010A (ja) * 1993-10-20 1997-04-22 ジ・アップジョン・カンパニー 抗関節炎剤および抗炎症剤としてのピリミジノン
WO2001016114A2 (en) * 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
WO2001019800A2 (en) * 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2001019802A1 (fr) * 1999-09-16 2001-03-22 Tanabe Seiyaku Co., Ltd. Composes cycliques aromatiques azotes a six elements
WO2001030768A1 (en) * 1999-10-27 2001-05-03 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001049287A1 (en) * 1999-12-30 2001-07-12 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001098278A1 (en) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002030462A2 (en) * 2000-10-13 2002-04-18 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
JP2004536796A (ja) * 2000-12-11 2004-12-09 トゥラリック インコーポレイテッド Ｃｘｃｒ３アンタゴニスト
JP2004515544A (ja) * 2000-12-11 2004-05-27 藤沢薬品工業株式会社 キナゾリノン誘導体
JP2002338466A (ja) * 2001-03-15 2002-11-27 Tanabe Seiyaku Co Ltd 医薬組成物
JP2005507876A (ja) * 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
JP2005510500A (ja) * 2001-10-26 2005-04-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ジヒドロキシピリミジンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
JP2005511543A (ja) * 2001-10-26 2005-04-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
JP2005525303A (ja) * 2001-12-06 2005-08-25 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
JPN6009059917, ＤＥ ＭＥＬＯ， Ｊ．Ｓ． ｅｔ ａｌ, "５−Ｆｌｕｏｒｏ−（３Ｈ）−ｐｙｒｉｍｉｄｉｎｅ−４−ｏｎｅｓ： ｓｙｎｔｈｅｓｉｓ， ｒｅａｃｔｉｖｉｔｙ ａｎｄ ｐｈａｒｍａｃｏｌｏｇｉｃａｌ ｐｒｏｐｅｒｔｉｅｓ", Ａｎｎａｌｅｓ Ｐｈａｒｍａｃｅｕｔｉｑｕｅｓ Ｆｒａｎｃａｉｓｅｓ, 1992, Ｖｏｌ．５０， Ｎｏ．１, ｐ．３９−５１ *
JPN6009059918, ＴＩＷＡＲＩ，Ｓ．Ｓ． ｅｔ ａｌ, "ＰＯＳＳＩＢＬＥ ＡＮＴＩＦＥＲＴＩＬＩＴＹ ＣＯＭＰＯＵＮＤＳ−ＰＡＲＴ ＩＩＩ：ＳＹＮＴＨＥＳＩＳ ＯＦ ２−ＨＩＰＰＵＲＹＬ−３−ＡＲＹＬＱＵＩＮＡＺＯＬＩＮＯＮＥＳ", Ｊ． Ｃｈｅｍ． Ｓｏｃ． Ｐａｋ．, 1981, ｖｏｌ．３， ｎｏ．４, ｐ．２１５−２１７ *
JPN6009059919, ＬＩＳ，Ｒ． ｅｔ ａｌ, "Ａ ｎｏｖｅｌ ｓｙｎｔｈｅｔｉｃ ｒｏｕｔｅ ｔｏ １，２−ｄｉｍｅｔｈｙｌ−５−ｐｈｅｎｙｌ−１Ｈ−ｉｍｉｄａｚｏ［４，５−ｂ］ｐｙｒｉｄｉｎ− ７−ｏｌ", Ｊｏｕｒｎａｌ ｏｆ Ｈｅｔｅｒｏｃｙｃｌｉｃ Ｃｈｅｍｉｓｔｒｙ, 1990, Ｖｏｌ．２７， Ｎｏ．３, ｐ．５３１−４ *
JPN6009059920, ＲＡＯ，Ｄ．Ａ． ｅｔ ａｌ, "ＳＹＮＴＨＥＳＩＳ Ａ． ＢＩＯＬＯＧＩＣＡＬ ＡＣＴＩＶＩＴＩＥＳ ＯＦ ＣＥＲＴＡＩＮ ＤＥＲＩＶＡＴＩＶＥＳ ＯＦ ３−ＡＲＹＬ−４（３Ｈ）−ＱＵＩＮＡＺＯＬＩＮＯＮＥＳ． ＰＡＲＴ ＩＩ", Ｊ． Ｉｎｄｉａｎ Ｃｈｅｍ． Ｓｏｃ．, 1985, ｖｏｌ．ＬＸＩＩ, ｐ．２３４−２３７ *
JPN6009059921, ＵＣＨＩＤＡ，Ｈ． ｅｔ ａｌ, "Ｒｅａｃｔｉｏｎｓ ｏｆ Ｎ−ａｃｙｌａｍｉｎｏａｃｅｔａｍｉｄｉｎｅ ｗｉｔｈ １，３−ｂｉｆｕｎｃｔｉｏｎａｌ ｃｏｍｐｏｕｎｄｓ", Ｂｕｌｌｅｔｉｎ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ ｏｆ Ｊａｐａｎ, 1973, Ｖｏｌ．４６， Ｎｏ．１０, ｐ．３２７７−８０ *
JPN7009005092, ＤＥＢＮＡＴＨ，Ａ．Ｋ． ｅｔ ａｌ, "Ｓｔｒｕｃｔｕｒｅ−ｂａｓｅｄ ｉｄｅｎｔｉｆｉｃａｔｉｏｎ ｏｆ ｓｍａｌｌ ｍｏｌｅｃｕｌｅ ａｎｔｉｖｉｒａｌ ｃｏｍｐｏｕｎｄｓ ｔａｒｇｅｔｅｄ ｔｏ ｔｈｅ ｇｐ４１ ｃｏｒｅ ｓｔｒｕｃ", ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ, 1999, ｖｏｌ．４２， ｎｏ．１７, ｐ．３２０３−３２０９ *
JPN7009005093, ＨＵＧＨＥＳ，Ｌ．Ｒ． ｅｔ ａｌ, "Ｑｕｉｎａｚｏｌｉｎｅ ａｎｔｉｆｏｌａｔｅ ｔｈｙｍｉｄｙｌａｔｅ ｓｙｎｔｈａｓｅ ｉｎｈｉｂｉｔｏｒｓ： ａｌｋｙｌ， ｓｕｂｓｔｉｔｕｔｅｄ ａｌｋｙｌ， ａｎｄ ａｒｙｌ ｓｕｂｓｔｉｔｕｅ", ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ, 1990, ｖｏｌ．３３， ｎｏ．１１, ｐ．３０６０−３０６７ *
JPN7009005094, ＫＡＴＡＧＩＲＩ，Ｎ． ｅｔ ａｌ, "Ｓｙｎｔｈｅｓｉｓ ｏｆ ｉｍｉｄａｚｏ［１，５−α］ｐｙｒｉｍｉｄｉｎｅｓ", Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ, 1983, Ｖｏｌ．３１， Ｎｏ．８, ｐ．２５４０−５１ *
JPN7009005095, ＨＯＮＭＡ，Ｙ． ｅｔ ａｌ, "Ｓｔｕｄｉｅｓ ｏｎ ａｎｔｉａｌｌｅｒｇｉｃ ａｇｅｎｔｓ． Ｉ． Ｐｈｅｎｙｌ−ｓｕｂｓｔｉｔｕｔｅｄ ｈｅｔｅｒｏｃｙｃｌｅｓ ｗｉｔｈ ａ ５−ｔｅｔｒａｚｏｌｙｌ ｏｒ Ｎ−（５−ｔｅｔ", Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ, 1982, Ｖｏｌ．３０， Ｎｏ．１２, ｐ．４３１４−２４ *
JPN7009005096, ＫＡＴＡＧＩＲＩ，Ｎ． ｅｔ ａｌ, "Ｒｅａｃｔｉｏｎ ｏｆ β−ａｍｉｎｏｃｒｏｔｏｎａｍｉｄｅ ｗｉｔｈ Ｎ−ａｃｙｌａｔｅｄ ａｍｉｎｏ ａｃｉｄ ｅｓｔｅｒｓ ｔｏ ｇｉｖｅ ２−ａｃｙｌａｍｉｎｏａｌｋｙｌ−６−ｍｅｔｈｙｌｐ", Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ, 1983, Ｖｏｌ．３１， Ｎｏ．７, ｐ．２２８８−９５ *
JPN7009005097, ＫＡＴＡＧＩＲＩ，Ｎ． ｅｔ ａｌ, "２−［（Ａｃｙｌａｍｉｎｏ）ｍｅｔｈｙｌ］−６−ｍｅｔｈｙｌｐｙｒｉｍｉｄｉｎ−４（３Ｈ）−ｏｎｅｓ． Ｎｏｖｅｌ ｐｒｅｃｕｒｓｏｒｓ ｆｏｒ ｔｈｅ ｓｙｎｔｈｅｓｉｓ ｏｆ ｉｍｉｄａｚｏ［１", Ｊｏｕｒｎａｌ ｏｆ Ｏｒｇａｎｉｃ Ｃｈｅｍｉｓｔｒｙ, 1982, Ｖｏｌ．４７， Ｎｏ．１, ｐ．１６７−９ *
JPN7009005098, ＳＨＵＴＯ，Ｙ． ｅｔ ａｌ, "Ｎｅｗ ｐｙｒｉｍｉｄｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ｗｉｔｈ ｓｉｄｅ ｃｈａｉｎｓ ｏｆ ａｍｉｎｏ ａｃｉｄｓ", Ａｇｒｉｃｕｌｔｕｒａｌ ａｎｄ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ, 1978, Ｖｏｌ．４２， Ｎｏ．１０, ｐ．１９３３−５ *
JPN7009005099, ＳＡＵＴＥＲ，Ｆ． ｅｔ ａｌ, "Ｎｏｖｅｌ ｂａｓｉｃａｌｌｙ ｓｕｂｓｔｉｔｕｔｅｄ ｐｙｒｉｍｉｄｉｎｅｓ ａｎｄ ｂｅｎｚｏｔｈｉｅｎｏｐｙｒｉｍｉｄｉｎｅｓ", Ａｒｃｈｉｖ ｄｅｒ Ｐｈａｒｍａｚｉｅ（Ｗｅｉｎｈｅｉｍ， Ｇｅｒｍａｎｙ）, 1977, Ｖｏｌ．３１０， Ｎｏ．４, ｐ．３３７−４３ *
JPN7009005100, ＵＣＨＩＤＡ，Ｈ． ｅｔ ａｌ, "Ｒｅａｃｔｉｏｎ ｏｆ ２−ｂｅｎｚｏｙｌａｍｉｎｏ−２−ｍｅｔｈｙｌｐｒｏｐｉｏｎａｍｉｄｉｎｅ ａｎｄ ２−ｂｅｎｚｏｙｌａｍｉｎｏａｃｅｔａｍｉｄｉｎｅ ｗｉｔｈ ｂｉｆｕｎｃｔｉｏｎａｌ ｃｏ", Ｂｕｌｌｅｔｉｎ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ ｏｆ Ｊａｐａｎ, 1974, Ｖｏｌ．４７， Ｎｏ．７, ｐ．１７２０−３ *
JPN7009005102, ＤＯＲＮＯＷ，Ａ． ｅｔ ａｌ, "Ｓｙｎｔｈｅｓｅｓ ｏｆ ｎｉｔｒｏｇｅｎ−ｃｏｎｔａｉｎｉｎｇ ｈｅｔｅｒｏｃｙｃｌｅｓ． ＸＸＩＩＩ． Ｔｈｅ ｐｒｅｐａｒａｔｉｏｎ ｏｆ ５−ａｃｅｔｙｌｏｘａｚｏｌｅｓ ａｎｄ ｔｈｅｉｒ", Ｃｈｅｍｉｓｃｈｅ Ｂｅｒｉｃｈｔｅ, 1960, Ｖｏｌ．９３, ｐ．１９９８−２００１ *

Also Published As

Publication number Publication date
PL373412A1 (en) 2005-08-22
NZ537076A (en) 2007-06-29
WO2003094839A8 (en) 2004-06-24
AU2003223786A1 (en) 2003-11-11
WO2003094839A2 (en) 2003-11-20
EP1503993A2 (en) 2005-02-09
MY140767A (en) 2010-01-15
BR0309892A2 (pt) 2011-04-05
US20070135432A1 (en) 2007-06-14
US7482343B2 (en) 2009-01-27
US7166595B2 (en) 2007-01-23
MXPA04011074A (es) 2005-06-08
US20040077662A1 (en) 2004-04-22
NO20045043L (no) 2005-02-08
ZA200409881B (en) 2006-04-26
CN1665788A (zh) 2005-09-07
RU2004135554A (ru) 2006-01-20
IL187528A0 (en) 2008-03-20
AR039985A1 (es) 2005-03-09
IS7520A (is) 2004-11-03
CN100491358C (zh) 2009-05-27
EP1503993A4 (en) 2006-05-03
IL165046A0 (en) 2005-12-18
TW200406387A (en) 2004-05-01
KR20050036911A (ko) 2005-04-20
WO2003094839A3 (en) 2004-09-16
CA2485148A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
JP2006508030A (ja) ピリミジノン化合物、組成物および方法
US7528137B2 (en) Compounds, compositions, and methods
US7041676B2 (en) Compounds, compositions, and methods
JP2005523312A (ja) 化合物、組成物および方法
US6949538B2 (en) Compounds, compositions, and methods
KR20050075356A (ko) 화합물, 조성물 및 방법
US7271167B2 (en) Compounds, compositions, and methods
JP2005539062A (ja) 化合物、組成物および方法
US20050197327A1 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100803